checkAd

     125  0 Kommentare SQZ Biotechnologies Announces Strategic Prioritization of SQZ Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer - Seite 3

    Lesen Sie auch


    The SQZ Biotechnologies Company Stock at the time of publication of the news with a fall of -5,28 % to 2,51USD on NYSE stock exchange (29. November 2022, 22:00 Uhr).

    Business Wire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von Business Wire (engl.)
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    SQZ Biotechnologies Announces Strategic Prioritization of SQZ Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer - Seite 3 SQZ Biotechnologies (NYSE: SQZ) today announced the strategic prioritization of its clinical portfolio to concentrate on the development of its second-generation enhanced Antigen Presenting Cells (eAPC) cell therapy program, focused on HPV16 …